A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
Fiche du document
21 janvier 2022
- doi: 10.1038/s41598-022-05058-5
- issn: 2045-2322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-022-05058-5
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35064152
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2045-2322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7D41964E18228
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Thymus-dependent lymphocytes Thymus-derived cells T lymphocytes Thymus-dependent cells Immune globulins Antibodies Immune serum globulinCiter ce document
J.K. Fierle et al., « A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors. », Serveur académique Lausannois, ID : 10.1038/s41598-022-05058-5
Métriques
Partage / Export
Résumé
Anti-tumor therapies that seek to exploit and redirect the cytotoxic killing and effector potential of autologous or syngeneic T cells have shown extraordinary promise and efficacy in certain clinical settings. Such cells, when engineered to express synthetic chimeric antigen receptors (CARs) acquire novel targeting and activation properties which are governed and orchestrated by, typically, antibody fragments specific for a tumor antigen of interest. However, it is becoming increasingly apparent that not all antibodies are equal in this regard, with a growing appreciation that 'optimal' CAR performance requires a consideration of multiple structural and contextual parameters. Thus, antibodies raised by classical approaches and intended for other applications often perform poorly or not at all when repurposed as CARs. With this in mind, we have explored the potential of an in vitro phenotypic CAR library discovery approach that tightly associates antibody-driven bridging of tumor and effector T cells with an informative and functionally relevant CAR activation reporter signal. Critically, we demonstrate the utility of this enrichment methodology for 'real world' de novo discovery by isolating several novel anti-mesothelin CAR-active scFv candidates.